Adlai Nortye Ltd. America... (ANL)
NASDAQ: ANL
· Real-Time Price · USD
1.77
-0.03 (-1.60%)
At close: Oct 01, 2025, 12:50 PM
-1.60% (1D)
| Bid | 1.75 |
| Market Cap | 18.48M |
| Revenue (ttm) | 6.49M |
| Net Income (ttm) | -54.06M |
| EPS (ttm) | -1.67 |
| PE Ratio (ttm) | -1.06 |
| Forward PE | -4.92 |
| Analyst | n/a |
| Dividends | n/a |
| Ask | 1.8 |
| Volume | 19,251 |
| Avg. Volume (20D) | 9,074 |
| Open | 1.82 |
| Previous Close | 1.80 |
| Day's Range | 1.71 - 1.82 |
| 52-Week Range | 1.10 - 3.89 |
| Beta | -0.87 |
| Ex-Dividend Date | n/a |
4 months ago · https://www.marketscreener.com
Adlai Nortye Ltd. Announces Topline Results of Phase III Buran Trial Evaluating Buparlisib in Combination with Paclitaxel for Recurrent or Metastatic HNSCCAdlai Nortye Ltd. announced topline results from its Phase III BURAN trial evaluating buparlisib (AN2025), a PI3K inhibitor, in combination with paclitaxel for the treatment of patients with recurrent...